Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Ibuprofen Use Associated with Reduced Risk of Death from Lung Cancer Among Smokers

XTALKS VITALS NEWS

Ibuprofen

Researchers from Ohio State University have found that the drug could reduce the risk of death due to lung cancer.

Share this!

December 13, 2016 | by Sarah Hand, M.Sc.

Ibuprofen is a commonly-used nonsteroidal anti-inflammatory drug (NSAID) for pain relief, however new research suggests that it may also be beneficial to current and former smokers. Researchers from Ohio State University have found that the drug could reduce the risk of death due to lung cancer.

Lung cancer is one of the most prevalent types of cancer in the US, with approximately 224,390 individuals diagnosed with the disease every year. It also represents the number one cause of cancer death in men and women.

Around 80 to 90 percent of all cases of lung cancer diagnosed in the US have been associated with smoking. Since chronic inflammation in the lungs caused by prolonged exposure to cigarette smoke has been associated with an increased risk of developing lung cancer, the researchers on the current study decided to investigate whether an anti-inflammatory medication – namely, ibuprofen – could help lower this risk.

The researchers analyzed data collected from 10,735 adults, as part of the Third National Health and Nutrition Examination Survey (NHANES III). During the initial enrollment period between 1988 and 1994, study participants were asked about their history of smoking, use of NSAIDs and additional lifestyle choices.



On average, study participants were followed for 18 years, with the researchers recording cause-of-death using the National Death Index until 2006. Using Cox proportional hazards regression models, the researchers studied the association between NSAID use and risk of lung cancer death.

In all, 269 of the participants in the initial survey died as a result of lung cancer, with 252 of those individuals having a history of smoking. In addition to this data, the researchers also analyzed the effects of NSAID use among a further 5,882 adults who were past or current smokers.

The team calculated that people with a history of smoking who used ibuprofen on a regular basis, had a 48 percent lower chance of dying from lung cancer, compared to smokers who did not take the NSAID. According to the researchers – who presented these results at the IASLC 17th World Conference on Lung Cancer (WCLC) – this link was not statistically significant.

“These results suggest that regular use of certain NSAIDs may be beneficial for high-risk subgroups of smokers as a lung cancer prevention strategy,” said Dr. Marisa Bittoni, of Ohio State University. While regular use of ibuprofen could mitigate lung cancer death risk, more research will need to be conducted to verify the link.


Keywords: NSAID, Lung Cancer, Ibuprofen


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.